Jeryl Hilleman

Jeri Hilleman joined our Board in July 2018. She has an extensive life sciences background that includes high growth commercial biopharma, med-tech and data science companies. Ms. Hilleman is Chief Financial Officer of Intersect ENT (Nasdaq: XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public companies, including Amyris, Symyx Technologies (acquired), Ocera (acquired) and Cytel (acquired). Ms. Hilleman is also a member of the Board of Directors and Audit Committee of NovoCure and served previously as a member of the Board of Directors and Chair of the Audit Committee of Xenoport, Inc. (acquired), a commercial biopharma company, for over ten years, from IPO through acquisition. Ms. Hilleman holds an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.